May. 7 at 12:17 PM
$RMTI
🚨🚨🚨
Rockwell Medical, Inc. reported first-quarter 2026 results showing slightly lower sales but stable losses and improved cash use.
Net sales were
$17.3 million, down 8% from
$18.9 million a year earlier, mainly from reduced DaVita purchases, partly offset by higher pricing and new customers.
Gross profit was
$2.9 million with a 17% margin, similar to last year, and net loss was
$1.6 million, or
$0.04 per share.
DaVita accounted for 7% of sales versus 27% in 2025, reducing customer concentration.
Operating cash outflow improved sharply to about
$0.2 million from
$3.5 million.
Rockwell ended March 31, 2026 with
$23.9 million in cash, cash equivalents and available-for-sale investments and working capital of
$27.1 million.
Management states these resources, plus
$13.1 million remaining under its at-the-market equity program, are expected to fund operations for at least 12 months.
